116 related articles for article (PubMed ID: 15531454)
61. IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome.
Cogliatti SB; Bertoni F; Zimmermann DR; Henz S; Diss TC; Ghielmini M; Schmid U
J Pathol; 2005 Jul; 206(3):320-7. PubMed ID: 15887292
[TBL] [Abstract][Full Text] [Related]
62. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes.
Takahashi H; Feuerhake F; Kutok JL; Monti S; Dal Cin P; Neuberg D; Aster JC; Shipp MA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3265-71. PubMed ID: 16740746
[TBL] [Abstract][Full Text] [Related]
63. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy.
Van Geelen CM; de Vries EG; de Jong S
Drug Resist Updat; 2004 Dec; 7(6):345-58. PubMed ID: 15790545
[TBL] [Abstract][Full Text] [Related]
64. Small B-cell neoplasms with typical mantle cell lymphoma immunophenotypes often include chronic lymphocytic leukemias.
Ho AK; Hill S; Preobrazhensky SN; Miller ME; Chen Z; Bahler DW
Am J Clin Pathol; 2009 Jan; 131(1):27-32. PubMed ID: 19095562
[TBL] [Abstract][Full Text] [Related]
65. Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling.
Rossin A; Derouet M; Abdel-Sater F; Hueber AO
Biochem J; 2009 Apr; 419(1):185-92, 2 p following 192. PubMed ID: 19090789
[TBL] [Abstract][Full Text] [Related]
66. Genetic variants in the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and death receptor (DR4) genes contribute to susceptibility to colorectal cancer in pakistani population.
Zahoor A; Mansoor Q; Farooqi AA; Fayyaz S; Naz G; Ismail M
Cell Mol Biol (Noisy-le-grand); 2015 Oct; 61(6):108-12. PubMed ID: 26518902
[TBL] [Abstract][Full Text] [Related]
67. Expression of BAFF-R and TACI in reactive lymphoid tissues and B-cell lymphomas.
Wada K; Maeda K; Tajima K; Kato T; Kobata T; Yamakawa M
Histopathology; 2009 Jan; 54(2):221-32. PubMed ID: 19207947
[TBL] [Abstract][Full Text] [Related]
68. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes.
Rubio-Moscardo F; Blesa D; Mestre C; Siebert R; Balasas T; Benito A; Rosenwald A; Climent J; Martinez JI; Schilhabel M; Karran EL; Gesk S; Esteller M; deLeeuw R; Staudt LM; Fernandez-Luna JL; Pinkel D; Dyer MJ; Martinez-Climent JA
Blood; 2005 Nov; 106(9):3214-22. PubMed ID: 16051735
[TBL] [Abstract][Full Text] [Related]
69. Mutations of the BIK gene in human peripheral B-cell lymphomas.
Arena V; Martini M; Luongo M; Capelli A; Larocca LM
Genes Chromosomes Cancer; 2003 Sep; 38(1):91-6. PubMed ID: 12874789
[TBL] [Abstract][Full Text] [Related]
70. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance.
Ozören N; Fisher MJ; Kim K; Liu CX; Genin A; Shifman Y; Dicker DT; Spinner NB; Lisitsyn NA; El-Deiry WS
Int J Oncol; 2000 May; 16(5):917-25. PubMed ID: 10762627
[TBL] [Abstract][Full Text] [Related]
71. Genetic variations in tumor ecrosis factor related apoptosis-inducing ligand receptor-1 (TRAIL-R1) gene and the susceptibility to b-cell non-hodgkin lymphoma (B-NHL) in Egypt.
Khorshied M; Soliman N; Khorshid O; Bakr S
Cancer Biomark; 2021; 32(4):451-458. PubMed ID: 34275891
[TBL] [Abstract][Full Text] [Related]
72. Familial lymphoid neoplasms in patients with mantle cell lymphoma.
Tort F; Camacho E; Bosch F; Harris NL; Montserrat E; Campo E
Haematologica; 2004 Mar; 89(3):314-9. PubMed ID: 15020270
[TBL] [Abstract][Full Text] [Related]
73. Insect bite-like reaction associated with mantle cell lymphoma: a report of two cases and review of the literature.
Dodiuk-Gad RP; Dann EJ; Bergman R
Int J Dermatol; 2004 Oct; 43(10):754-8. PubMed ID: 15485536
[TBL] [Abstract][Full Text] [Related]
74. Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas.
Arai T; Akiyama Y; Okabe S; Saito K; Iwai T; Yuasa Y
Cancer Lett; 1998 Nov; 133(2):197-204. PubMed ID: 10072170
[TBL] [Abstract][Full Text] [Related]
75. Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas.
Heredia-Galvez B; Ruiz-Cosano J; Torres-Moreno D; Español I; Morales-Lara MJ; Pérez-Ceballos E; González-Conejero R; Gutiérrez-Cívicos R; Vicente V; Pérez-Guillermo M; Conesa-Zamora P
Ann Hematol; 2014 Feb; 93(2):243-7. PubMed ID: 23959437
[TBL] [Abstract][Full Text] [Related]
76. Association of DR4 (TRAIL-R1) polymorphisms with cancer risk in Caucasians: an updated meta-analysis.
Chen W; Tang WR; Zhang M; Chang K; Wei YL
Asian Pac J Cancer Prev; 2014; 15(6):2889-92. PubMed ID: 24761920
[TBL] [Abstract][Full Text] [Related]
77. Mutation of the DR5/TRAIL receptor 2 gene is infrequent in hepatocellular carcinoma.
Jeng YM; Hsu HC
Cancer Lett; 2002 Jul; 181(2):205-8. PubMed ID: 12175536
[TBL] [Abstract][Full Text] [Related]
78. Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.
Bogusz AM; Bagg A
Leuk Lymphoma; 2016 Sep; 57(9):1991-2013. PubMed ID: 27121112
[TBL] [Abstract][Full Text] [Related]
79. PPP2R1B gene in chronic lymphocytic leukemias and mantle cell lymphomas.
Zhu Y; Loukola A; Monni O; Kuokkanen K; Franssila K; Elonen E; Vilpo J; Joensuu H; Kere J; Aaltonen L; Knuutila S
Leuk Lymphoma; 2001 Mar; 41(1-2):177-83. PubMed ID: 11342371
[TBL] [Abstract][Full Text] [Related]
80. Inactivating mutations of KILLER/DR5 gene in gastric cancers.
Park WS; Lee JH; Shin MS; Park JY; Kim HS; Kim YS; Park CH; Lee SK; Lee SH; Lee SN; Kim H; Yoo NJ; Lee JY
Gastroenterology; 2001 Nov; 121(5):1219-25. PubMed ID: 11677215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
